Imugene COO resigns

Imugene (ASX:IMU), a clinical-stage immuno-oncology company, announced that Dr. Bradley Glover has resigned from his role as COO to focus on other business interests.

The company said the transition of responsibilities will be carefully managed and will not affect ongoing operations or programs.

Reflecting on his tenure, Dr. Glover said, "It has been a true privilege to serve as COO of Imugene and to work alongside such a talented and committed team advancing innovative oncology programs. I am proud of what we have achieved together, particularly the progress of azer-cel, and I wish the Company continued success as it moves into its next phase."

At the time of reporting, Imugene's share price was $0.39.